Pregabalin In Partial Seizures (PREPS): An Open-Label, Multicenter Add On Therapy Trial
Status:
Terminated
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the clinical improvement by partial seizures
reduction, safety and tolerability of subjects having partial epilepsy related to the
adjunction of pregabalin BID (75 to 300mg day titration, BID) to existing standard AED
(Antiepileptic drugs).
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.